Vanessa Meletia Bala

Dr. Vanessa Meletia Bala

Hygeia Hospital, Athens, Attikí, Greece
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VBVanessa Meletia Bala
Vanessa Meletia Bala
Dimitra Ioanna LampropoulouDimitra Ioanna Lampropoulou
Dimitra Ioanna Lampropoulou
SGStamatiki Grammatikaki
Stamatiki Grammatikaki
Vassilis KoulouliasVassilis Kouloulias
Vassilis Kouloulias
NLNefeli Lagopati
Nefeli Lagopati
Maria GazouliMaria Gazouli
Maria Gazouli
Hyperthermia has the potential to damage cancerous tissue by increasing the body temperature. However, targeting cancer cells whilst protecting the surrounding tissues is often challenging, especially when implemented in clinical practice. In this direction, there are data showing that the combination of nanotechnology and hyperthermia offers more successful penetration of nanoparticles in the tumor environment, thus allowing targeted hyperthermia in the region of interest. At the same time, unlike radiotherapy, the use of non-ionizing radiation makes hyperthermia an attractive therapeutic option. This review summarizes the existing literature regarding the use of hyperthermia and nanoparticles in cancer, with a focus on nanoparticle-induced cytotoxicity mechanisms.

7 August 2023 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
MMMaria Mitsogianni
Maria Mitsogianni
APAthanasios Papatsoris
Athanasios Papatsoris
VBVanessa Meletia Bala
Vanessa Meletia Bala
HIHussein Issa
Hussein Issa
MMMohammad Moussa
Mohammad Moussa
IMIraklis Mitsogiannis
Iraklis Mitsogiannis
Prostate cancer is the most common malignancy in the male. Androgen-deprivation therapy (ADT) has been the mainstay in the treatment of metastatic prostate cancer however, due to the outgrowth of castration-resistant cell population the disease inevitably progresses to an aggressive, difficult to handle stage. We have reviewed the literature regarding hormonal-directed therapy prostate cancer. New agents, namely abiraterone acetate, combined with prednisone, and next generation antiandrogens (enzalutamide, apalutamide and darolutamide) have shown considerable efficacy, not only in patients with metastatic but also in those with non-metastatic disease, either castration resistant (CRPC) or hormone sensitive (HSPC). The addition of abiraterone and of the second-generation antiandrogens to our therapeutic armamentarium has improved prognosis ofprostate cancer in the last decade. Abiraterone is a viable option in patients with metastatic disease (hormone-sensitive and castration-resistant), whereas all next-generation antiandrogens have demonstrated efficacy in terms of metastasis-free and overall survival in non-metastatic CRPC. In addition, enzalutamide has also been found efficacious in mCRPC and mHSPC, while apalutamide in mHSPC. Currently there are no reliable data to indicate a potential superiority of one of these agents over the others in CRPC or HSPC as there are no relevant head to head studies . Sequencing hormone treatment modalities, chemotherapies and immunotherapies have not reached a consensus as yet. Randomized controlled trials are warranted to clearly define the role of novel antiandrogens in the treatment of prostate cancer. The choice of treatment should be individualized following discussion with the patient .

31 January 2022 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
Dimitra Ioanna LampropoulouDimitra Ioanna Lampropoulou
Dimitra Ioanna Lampropoulou
VBVanessa Meletia Bala
Vanessa Meletia Bala
EZEleni Zerva
Eleni Zerva
EPEvangelia Pliakou
Evangelia Pliakou
DFDIMITRIOS FILIPPOU
DIMITRIOS FILIPPOU
GAGerasimos Aravantinos
Gerasimos Aravantinos
Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments. Methodology: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection. Results: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients. Conclusions: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.

18 March 2022 in Molecular and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
VBVanessa Meletia Bala
Vanessa Meletia Bala
MMMaria Mitsogianni
Maria Mitsogianni
KLKonstantinos Laschos
Konstantinos Laschos
EPEvangelia Pliakou
Evangelia Pliakou
ELEirini Lazaridi
Eirini Lazaridi
GAGerasimos Aravantinos
Gerasimos Aravantinos
BRAF/MEK inhibitors are considered standard of care in the treatment of advanced BRAF‑mutated malignant melanoma, and have been, in rare cases, associated with granulomatous reactions, mostly limited to skin lesions. The present study reported the case of a patient with metastatic melanoma developing a sarcoid‑like reaction manifesting as asymptomatic mediastinal and right hilar lymphadenopathy while on antineoplastic therapy with dabrafenib and trametinib. To the best of our knowledge, this is the first reported case of isolated lymphadenopathy as a manifestation of drug‑induced sarcoid‑like reaction under dabrafenib and trametinib. Overall, only 17 other cases of granulomatosis have been reported in the literature. Although uncommon, such reactions should be considered in the differential diagnosis of lymph node enlargement, and distinguishing them from tumor progress is important and can be challenging in clinical practice.